Transabdominal bowel ultrasound for monitoring efficacy of vedolizumab treatment in patients with moderate-to-severe ulcerative colitis
10.13929/j.issn.1003-3289.2025.10.017
- VernacularTitle:经腹肠道超声监测维得利珠单抗治疗中-重度溃疡性结肠炎效果
- Author:
Lihua YAN
1
;
Xiaodong LUO
;
Shuochun CHEN
;
Xinying YU
;
Ziyi QIU
;
Yixin CHEN
;
Caihe CHEN
;
Buzhi SONG
;
Yingjia LI
Author Information
1. 南方医科大学南方医院超声医学科,广东 广州 510515
- Publication Type:Journal Article
- Keywords:
colitis,ulcerative;
antibodies,monoclonal,humanized;
treatment outcome;
colon,sigmoid;
ultrasonography
- From:
Chinese Journal of Medical Imaging Technology
2025;41(10):1687-1690
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the value of transabdominal bowel ultrasound for monitoring therapeutic efficacy of vedolizumab in patients with moderate-to-severe ulcerative colitis.Methods Totally 47 ulcerative colitis patients with Mayo endoscopic score(MES)≥2 and treated with vedolizumab were retrospectively included.Transabdominal bowel ultrasound examinations were performed at baseline,at the end of induction therapy,also 3 and 6 months after maintenance therapy,while colonoscopy was performed at baseline and 6 months after maintenance therapy.According to colonoscopy results 6 months after maintenance therapy,the patients were divided into improved group(MES≤1 or MES reduction≥1,n=25)and non-improved group(n=22),and ultrasonic findings of sigmoid colon were compared between and within groups.Results At baseline,no significant difference of ultrasonic findings of sigmoid colon was observed between groups(all P＞0.05),whereas differences of bowel wall thickness at the end of induction therapy,of Limberg grade and abnormal perienteric lymph nodes 3 months after maintenance therapy,as well as bowel wall stratification 6 months after maintenance therapy were noticed between groups(all P＜0.05).Within improved group,compared with those in baseline,bowel wall thickness improved at all time points after the beginning of treatment,Limberg grade improved 3 and 6 months after maintenance therapy,while bowel wall stratification,abnormal perienteric lymph node and perienteric fat edema improved 6 months after maintenance therapy(all P＜0.05).Meanwhile,no significant change of ultrasonic findings of sigmoid colon was observed in non-improved group during the above periods(all P＞0.05).Conclusion Transabdominal bowel ultrasound could be used to accurately monitor the therapeutic efficacy of vedolizumab in patients with moderate-to-severe ulcerative colitis.
